Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study
oleh: Heesun J. Rogers, James W. Vardiman, John Anastasi, Gordana Raca, Natasha M. Savage, Athena M. Cherry, Daniel Arber, Erika Moore, Jennifer JD. Morrissette, Adam Bagg, Yen-Chun Liu, Susan Mathew, Attilio Orazi, Pei Lin, Sa A. Wang, Carlos E. Bueso-Ramos, Kathryn Foucar, Robert P. Hasserjian, Ramon V. Tiu, Matthew Karafa, Eric D. Hsi
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2014-05-01 |
Deskripsi
Acute myeloid leukemia and myelodysplastic syndrome with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) have a poor prognosis. Indeed, the inv(3)(q21q26.2)/t(3;3)(q21;q26.2) has been recognized as a poor risk karyotype in the revised International Prognostic Scoring System. However, inv(3)(q21q26.2)/t(3;3)(q21;q26.2) is not among the cytogenetic abnormalities pathognomonic for diagnosis of acute myeloid leukemia irrespective of blast percentage in the 2008 WHO classification. This multicenter study evaluated the clinico-pathological features of acute myeloid leukemia/myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and applied the revised International Prognostic Scoring System to myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). A total of 103 inv(3)(q21q26.2)/t(3;3)(q21;q26.2) patients were reviewed and had a median bone marrow blast count of 4% in myelodysplastic syndrome (n=40) and 52% in acute myeloid leukemia (n=63) (P